Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03971617 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease
A Phase 2 study, sponsored by Stony Brook University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03971617: Clinical Trial Phase 2 study, sponsored by Stony Brook University.
NCT03971617 is a Phase 2 study that was terminated before completion, run by Stony Brook University. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03971617, a Phase 2 study, was terminated before completion, sponsored by Stony Brook University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study is a placebo-controlled, double-blind trial that will investigate the safety and tolerability of molecular hydrogen, a promising antioxidant agent, in patients with early-stage Parkinson's Disease. The medication will be administered orally as 8 ounces of hydrogen-enriched drinking water twice a day over the course of one year.
Primary Outcome
Number of treatment-emergent adverse events \[safety and tolerability\] of H2-enriched water in patients with Parkinson's disease (PD).
Interventions
- DRUG Placebo oral tablet
- DRUG Hydrogen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-05-29 |
| Est. Completion | 2021-04-29 |
| Phase | Phase 2 |
Why NCT03971617 stopped before completion
NCT03971617 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT03971617 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03971617 about?
NCT03971617 is a clinical study titled "Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease". This study is a placebo-controlled, double-blind trial that will investigate the safety and tolerability of molecular hydrogen, a promising antioxidant agent, in patients with early-stage Parkinson's Disease. The medication will be administered orally as 8 ounces of hydrogen-enriched drinking water ...
What is the current status of trial NCT03971617?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2019-05-29. Estimated completion is 2021-04-29.
What interventions are being tested in trial NCT03971617?
The interventions under investigation include: Placebo oral tablet (DRUG), Hydrogen (DRUG).
Who is sponsoring clinical trial NCT03971617?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03971617's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI